We conduct development of analytical methods and analyses of biomarkers or biopharmaceuticals for pharmacodynamic assessment, mainly with ligand binding assay (LBA) using commercially available kits.Ligand binding assay (LBA)
We analyze various biomarkers, e.g. GLP-1, GIP, and DPP IV activity for diabetes, CETP concentration, CETP activity, and angiotensin II for cardiovascular disease, GST, KIM-1, and FGF-23 for renal dysfunction, and cytokines/chemokines and lymphocyte subsets for inflammatory disease. We also conduct analyses of protein preparations including antibody drugs and their anti-drug antibodies (ADAs) in biological samples (serum, plasma, etc.).
Simultaneous quantification of different cytokines and chemokines by
MSD ECL System (Sector Imager 6000 and MESO QuickPlex SQ120) Bio-Plex Suspension Array System